{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:41:25Z","timestamp":1790138485835,"version":"4.0.1"},"reference-count":209,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01783-z","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:28:42Z","timestamp":1751380122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5244-2972","authenticated-orcid":false,"given":"Mahdis","family":"Abdar Esfahani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7120-9173","authenticated-orcid":false,"given":"Nazli","family":"Servatian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Jihad Hemid","family":"Al-Athari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaf Salah Mehdi","family":"Khafaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamideh","family":"Rahmani Seraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"18","key":"1783_CR1","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1101\/gad.284109.116","volume":"30","author":"D Hu","year":"2016","unstructured":"Hu D, Shilatifard A. Epigenetics of hematopoiesis and hematological malignancies. Genes Dev. 2016;30(18):2021\u201341.","journal-title":"Genes Dev"},{"issue":"1","key":"1783_CR2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbcan.2013.04.001","volume":"1836","author":"L Vecchio","year":"2013","unstructured":"Vecchio L, et al. Importance of epigenetic changes in cancer etiology, pathogenesis, clinical profiling, and treatment: what can be learned from hematologic malignancies? Biochim Biophys Acta (BBA) Rev Cancer. 2013;1836(1):90\u2013104.","journal-title":"Biochim Biophys Acta (BBA) Rev Cancer"},{"issue":"17","key":"1783_CR3","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2005.16.600","volume":"23","author":"KN Bhalla","year":"2005","unstructured":"Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol. 2005;23(17):3971\u201393.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1783_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2005.01.006","volume":"20","author":"O Galm","year":"2006","unstructured":"Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 2006;20(1):1\u201313.","journal-title":"Blood Rev"},{"issue":"9","key":"1783_CR5","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/ni.3517","volume":"17","author":"P Ntziachristos","year":"2016","unstructured":"Ntziachristos P, Abdel-Wahab O, Aifantis I. Emerging concepts of epigenetic dysregulation in hematological malignancies. Nat Immunol. 2016;17(9):1016\u201324.","journal-title":"Nat Immunol"},{"issue":"10","key":"1783_CR6","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00277-016-2636-8","volume":"95","author":"L Benetatos","year":"2016","unstructured":"Benetatos L, Vartholomatos G. On the potential role of DNMT1 in acute myeloid leukemia and myelodysplastic syndromes: not another mutated epigenetic driver. Ann Hematol. 2016;95(10):1571\u201382.","journal-title":"Ann Hematol"},{"issue":"3","key":"1783_CR7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41568-019-0109-9","volume":"19","author":"PA Jones","year":"2019","unstructured":"Jones PA, et al. Epigenetic therapy in immune-oncology. Nat Rev Cancer. 2019;19(3):151\u201361.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"1783_CR8","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nbt.1678","volume":"28","author":"TK Kelly","year":"2010","unstructured":"Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010;28(10):1069\u201378.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"1783_CR9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/17474086.2018.1453802","volume":"11","author":"SR Bohl","year":"2018","unstructured":"Bohl SR, Bullinger L, R\u00fccker FG. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia. Expert Rev Hematol. 2018;11(5):361\u201371.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"1783_CR10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark Res. 2025;13(1):28.","journal-title":"Biomark Res"},{"issue":"2","key":"1783_CR11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2009.02.042","volume":"280","author":"AJ Frew","year":"2009","unstructured":"Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 2009;280(2):125\u201333.","journal-title":"Cancer Lett"},{"key":"1783_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-019-0762-x","volume":"21","author":"S Genta","year":"2019","unstructured":"Genta S, Pirosa MC, Stathis A. BET and EZH2 inhibitors: novel approaches for targeting cancer. Curr Oncol Rep. 2019;21:1\u201310.","journal-title":"Curr Oncol Rep"},{"issue":"7782","key":"1783_CR13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299\u2013309.","journal-title":"Nature"},{"issue":"6","key":"1783_CR14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12032-025-02742-0","volume":"42","author":"MJ Saadh","year":"2025","unstructured":"Saadh MJ, et al. Mesenchymal stem cell-derived exosomes: a novel therapeutic frontier in hematological disorders. Med Oncol. 2025;42(6):199.","journal-title":"Med Oncol"},{"issue":"8","key":"1783_CR15","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/1878-0261.12744","volume":"14","author":"P Blecua","year":"2020","unstructured":"Blecua P, Martinez-Verbo L, Esteller MJMO. The DNA methylation landscape of hematological malignancies: an update. Mol Oncol. 2020;14(8):1616\u201339.","journal-title":"Mol Oncol"},{"issue":"7","key":"1783_CR16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jgg.2020.04.006","volume":"47","author":"N-M Hoang","year":"2020","unstructured":"Hoang N-M, Rui L. DNA methyltransferases in hematological malignancies. J Genet Genom. 2020;47(7):361\u201372.","journal-title":"J Genet Genom"},{"issue":"1","key":"1783_CR17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1101\/gad.268425.115","volume":"30","author":"BJ Shields","year":"2016","unstructured":"Shields BJ, et al. Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a. Genes Dev. 2016;30(1):78\u201391.","journal-title":"Genes Dev"},{"key":"1783_CR18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pharmthera.2017.11.002","volume":"184","author":"GD Ginder","year":"2018","unstructured":"Ginder GD, Williams DC Jr. Readers of DNA methylation, the MBD family as potential therapeutic targets. Pharmacol Ther. 2018;184:98\u2013111.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"1783_CR19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.14739","volume":"178","author":"X Zhang","year":"2017","unstructured":"Zhang X, et al. Research on the epigenetic regulation mechanism of the PTPN 6 gene in advanced chronic myeloid leukaemia. Br J Haematol. 2017;178(5):728\u201338.","journal-title":"Br J Haematol"},{"key":"1783_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010633","author":"L Kalinkova","year":"2022","unstructured":"Kalinkova L, et al. Targeting DNA methylation in leukemia, myelodysplastic syndrome, and lymphoma: a potential diagnostic, prognostic, and therapeutic tool. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms24010633.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1783_CR21","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.stem.2023.07.001","volume":"30","author":"Y Li","year":"2023","unstructured":"Li Y, et al. TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal. Cell Stem Cell. 2023;30(8):1072-1090.e10.","journal-title":"Cell Stem Cell"},{"key":"1783_CR22","doi-asserted-by":"crossref","unstructured":"Aval OS et al. Galectin-9: a double-edged sword in acute myeloid leukemia. Ann Hematol.vol 25, pg 1-14 2025.","DOI":"10.1007\/s00277-025-06387-x"},{"key":"1783_CR23","doi-asserted-by":"crossref","first-page":"768913","DOI":"10.3389\/fgene.2021.768913","volume":"12","author":"EK Elliott","year":"2021","unstructured":"Elliott EK, et al. Epigenetic regulation of miR-92a and TET2 and their association in non-Hodgkin lymphoma. Front Genet. 2021;12:768913.","journal-title":"Front Genet"},{"issue":"10","key":"1783_CR24","doi-asserted-by":"crossref","first-page":"e1006193","DOI":"10.1371\/journal.pgen.1006193","volume":"12","author":"M Stahl","year":"2016","unstructured":"Stahl M, et al. Epigenetics in cancer: a hematological perspective. PLoS Genet. 2016;12(10):e1006193.","journal-title":"PLoS Genet"},{"key":"1783_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081930","author":"K Dunphy","year":"2021","unstructured":"Dunphy K, et al. Current methods of post-translational modification analysis and their applications in blood cancers. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13081930.","journal-title":"Cancers (Basel)"},{"key":"1783_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s12038-019-9969-0","author":"NW Birch","year":"2020","unstructured":"Birch NW, Shilatifard A. The role of histone modifications in leukemogenesis. J Biosci. 2020. https:\/\/doi.org\/10.1007\/s12038-019-9969-0.","journal-title":"J Biosci"},{"key":"1783_CR27","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00432-016-2174-8","volume":"142","author":"V Sch\u00e4fer","year":"2016","unstructured":"Sch\u00e4fer V, et al. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia. J Cancer Res Clin Oncol. 2016;142:1641\u201350.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1783_CR28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11033-024-10200-9","volume":"52","author":"L Rajabi","year":"2025","unstructured":"Rajabi L, et al. Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53. Mol Biol Rep. 2025;52(1):102.","journal-title":"Mol Biol Rep"},{"issue":"36","key":"1783_CR29","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1073\/pnas.1619555114","volume":"114","author":"H Hashwah","year":"2017","unstructured":"Hashwah H, et al. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth. Proc Natl Acad Sci U S A. 2017;114(36):9701\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"1783_CR30","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ajh.27385","volume":"99","author":"K Bauer","year":"2024","unstructured":"Bauer K, et al. BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL. Am J Hematol. 2024;99(9):1721\u201331.","journal-title":"Am J Hematol"},{"issue":"5","key":"1783_CR31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1021\/acs.biochem.7b01152","volume":"57","author":"SE Jones","year":"2018","unstructured":"Jones SE, Olsen L, Gajhede M. Structural basis of histone demethylase KDM6B histone 3 lysine 27 specificity. Biochemistry. 2018;57(5):585\u201392.","journal-title":"Biochemistry"},{"issue":"1","key":"1783_CR32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","volume":"19","author":"P Wang","year":"2020","unstructured":"Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis. Mol Cancer. 2020;19(1):5.","journal-title":"Mol Cancer"},{"key":"1783_CR33","doi-asserted-by":"crossref","first-page":"741746","DOI":"10.3389\/fonc.2021.741746","volume":"11","author":"J Zhang","year":"2021","unstructured":"Zhang J, Gao X, Yu L. Roles of histone deacetylases in acute myeloid leukemia with fusion proteins. Front Oncol. 2021;11:741746.","journal-title":"Front Oncol"},{"issue":"8","key":"1783_CR34","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","volume":"29","author":"M Yamagishi","year":"2019","unstructured":"Yamagishi M, et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019;29(8):2321-2337.e7.","journal-title":"Cell Rep"},{"issue":"1","key":"1783_CR35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41392-023-01342-6","volume":"8","author":"A Zhao","year":"2023","unstructured":"Zhao A, et al. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. Signal Transduct Target Ther. 2023;8(1):71.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"1783_CR36","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.3390\/ijms23105801","volume":"23","author":"IV Bure","year":"2022","unstructured":"Bure IV, Nemtsova MV, Kuznetsova EBJIJoMS. Histone modifications and non-coding RNAs: mutual epigenetic regulation and role in pathogenesis. Int J Mol Sci. 2022;23(10):5801.","journal-title":"Int J Mol Sci"},{"key":"1783_CR37","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1146\/annurev-biochem-062917-012332","volume":"87","author":"DL Brautigan","year":"2018","unstructured":"Brautigan DL, Shenolikar S. Protein serine\/threonine phosphatases: keys to unlocking regulators and substrates. Annu Rev Biochem. 2018;87:921\u201364.","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"1783_CR38","first-page":"313","volume":"136","author":"O Molina","year":"2020","unstructured":"Molina O, et al. Impaired condensin complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL. Blood. 2020;136(3):313\u201327.","journal-title":"Blood"},{"issue":"5","key":"1783_CR39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000477737","volume":"84","author":"G M\u00e9hes","year":"2017","unstructured":"M\u00e9hes G, et al. Distinct dynamics of mitotic transition in B-cell lymphoma and reactive B-cell lymphoproliferations determined by H3S10 phosphohistone immunolabeling. Pathobiology. 2017;84(5):243\u201350.","journal-title":"Pathobiology"},{"key":"1783_CR40","doi-asserted-by":"crossref","first-page":"102490","DOI":"10.1016\/j.bcmd.2020.102490","volume":"86","author":"Y Pan","year":"2021","unstructured":"Pan Y, et al. RNF220 promotes the proliferation of leukaemic cells and reduces the degradation of the Cyclin D1 protein through USP22. Blood Cells Mol Dis. 2021;86:102490.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"1783_CR41","first-page":"8835714","volume":"2020","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, et al. The function of SUMOylation and its role in the development of cancer cells under stress conditions: a systematic review. Stem Cells Int. 2020;2020(1):8835714.","journal-title":"Stem Cells Int"},{"issue":"4","key":"1783_CR42","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/CM9.0000000000000624","volume":"133","author":"FY Wang","year":"2020","unstructured":"Wang FY, Gu ZY, Gao CJ. Emerging role of long non-coding RNAs in normal and malignant hematopoiesis. Chin Med J (Engl). 2020;133(4):462\u201373.","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"1783_CR43","doi-asserted-by":"crossref","first-page":"e90231","DOI":"10.1371\/journal.pone.0090231","volume":"9","author":"S Mei","year":"2014","unstructured":"Mei S, et al. Dendritic cell-associated miRNAs are modulated via chromatin remodeling in response to different environments. PLoS ONE. 2014;9(4):e90231.","journal-title":"PLoS ONE"},{"issue":"10","key":"1783_CR44","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/cas.12766","volume":"106","author":"LH Oliveira","year":"2015","unstructured":"Oliveira LH, et al. Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia. Cancer Sci. 2015;106(10):1264\u201377.","journal-title":"Cancer Sci"},{"key":"1783_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137156","author":"L Anelli","year":"2021","unstructured":"Anelli L, et al. Dysregulation of miRNA in leukemia: exploiting miRNA expression profiles as biomarkers. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22137156.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1783_CR46","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.3892\/or.2016.5147","volume":"36","author":"YY Zhang","year":"2016","unstructured":"Zhang YY, et al. Role of HOTAIR in the diagnosis and prognosis of acute leukemia. Oncol Rep. 2016;36(6):3113\u201322.","journal-title":"Oncol Rep"},{"issue":"8","key":"1783_CR47","volume":"36","author":"J Huang","year":"2022","unstructured":"Huang J, et al. Epigenetic silencing of E-cadherin gene induced by lncRNA MALAT-1 in acute myeloid leukaemia. J Clin Lab Anal. 2022;36(8): e24556.","journal-title":"J Clin Lab Anal"},{"issue":"10","key":"1783_CR48","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1080\/15476286.2020.1854520","volume":"18","author":"L Hu","year":"2021","unstructured":"Hu L, et al. Long non-coding RNA HOTAIR regulates myeloid differentiation through the upregulation of p21 via miR-17-5p in acute myeloid leukaemia. RNA Biol. 2021;18(10):1434\u201344.","journal-title":"RNA Biol"},{"issue":"1","key":"1783_CR49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hon.2776","volume":"39","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. The role of long non-coding RNAs and downstream signaling pathways in leukemia progression. Hematol Oncol. 2021;39(1):27\u201340.","journal-title":"Hematol Oncol"},{"key":"1783_CR50","doi-asserted-by":"crossref","first-page":"679634","DOI":"10.3389\/fonc.2021.679634","volume":"11","author":"FY Yao","year":"2021","unstructured":"Yao FY, et al. M(6)A modification of lncRNA NEAT1 regulates chronic myelocytic leukemia progression via miR-766-5p\/CDKN1A axis. Front Oncol. 2021;11:679634.","journal-title":"Front Oncol"},{"issue":"16","key":"1783_CR51","doi-asserted-by":"crossref","first-page":"12842","DOI":"10.18632\/oncotarget.24401","volume":"9","author":"A Garitano-Trojaola","year":"2018","unstructured":"Garitano-Trojaola A, et al. Deregulation of linc-PINT in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells. Oncotarget. 2018;9(16):12842\u201352.","journal-title":"Oncotarget"},{"issue":"7754","key":"1783_CR52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-019-1115-5","volume":"569","author":"D Barisic","year":"2019","unstructured":"Barisic D, et al. Mammalian ISWI and SWI\/SNF selectively mediate binding of distinct transcription factors. Nature. 2019;569(7754):136\u201340.","journal-title":"Nature"},{"issue":"1","key":"1783_CR53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12943-023-01736-8","volume":"22","author":"A Andrades","year":"2023","unstructured":"Andrades A, et al. SWI\/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities. Mol Cancer. 2023;22(1):39.","journal-title":"Mol Cancer"},{"issue":"39","key":"1783_CR54","doi-asserted-by":"crossref","first-page":"64071","DOI":"10.18632\/oncotarget.11773","volume":"7","author":"CM Lindqvist","year":"2016","unstructured":"Lindqvist CM, et al. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes. Oncotarget. 2016;7(39):64071\u201388.","journal-title":"Oncotarget"},{"issue":"8","key":"1783_CR55","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s12094-017-1633-2","volume":"19","author":"M Cuadros","year":"2017","unstructured":"Cuadros M, et al. BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines. Clin Transl Oncol. 2017;19(8):1010\u20137.","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"1783_CR56","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1038\/s41375-024-02331-6","volume":"38","author":"H Kim","year":"2024","unstructured":"Kim H, et al. Oncogenic dependency on SWI\/SNF chromatin remodeling factors in T-cell acute lymphoblastic leukemia. Leukemia. 2024;38(9):1906\u201317.","journal-title":"Leukemia"},{"issue":"1","key":"1783_CR57","volume":"10","author":"D Xiong","year":"2023","unstructured":"Xiong D, Zhang L, Sun Z-JJMMR. Targeting the epigenome to reinvigorate T cells for cancer immunotherapy. Mil Med Res. 2023;10(1): 59.","journal-title":"Mil Med Res"},{"issue":"1","key":"1783_CR58","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/nar\/gkab1211","volume":"50","author":"A Yoshida","year":"2022","unstructured":"Yoshida A, et al. Recognition of G-quadruplex RNA by a crucial RNA methyltransferase component, METTL14. Nucleic Acids Res. 2022;50(1):449\u201357.","journal-title":"Nucleic Acids Res"},{"key":"1783_CR59","doi-asserted-by":"publisher","DOI":"10.1080\/15476286.2024.2307732","author":"D Benak","year":"2024","unstructured":"Benak D, et al. Epitranscriptomic regulation in fasting hearts: implications for cardiac health. RNA Biol. 2024. https:\/\/doi.org\/10.1080\/15476286.2024.2307732.","journal-title":"RNA Biol"},{"issue":"1","key":"1783_CR60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40364-023-00495-4","volume":"11","author":"X Yang","year":"2023","unstructured":"Yang X, et al. EIF4A3-induced circ_0001187 facilitates AML suppression through promoting ubiquitin-proteasomal degradation of METTL3 and decreasing m6A modification level mediated by miR-499a-5p\/RNF113A pathway. Biomark Res. 2023;11(1):59.","journal-title":"Biomark Res"},{"issue":"11","key":"1783_CR61","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1002\/mco2.787","volume":"5","author":"X Chen","year":"2024","unstructured":"Chen X. RNA modification in normal hematopoiesis and hematologic malignancies. MedComm. 2024;5(11):e787.","journal-title":"MedComm"},{"key":"1783_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/cells11091403","author":"VE Kumar","year":"2022","unstructured":"Kumar VE, et al. Targeting epigenetic modifiers of tumor plasticity and cancer stem cell behavior. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11091403.","journal-title":"Cells"},{"issue":"1","key":"1783_CR63","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","volume":"8","author":"J Yang","year":"2023","unstructured":"Yang J, et al. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):210.","journal-title":"Signal Transduct Target Ther"},{"key":"1783_CR64","doi-asserted-by":"crossref","unstructured":"Yusoff NA et al. Exploring epigenetic complexity in regulation of hematopoietic stem cells niche: a mechanistic journey from normal to malignant hematopoiesis. Adv Exp Med Biol. vol 846, 2025.","DOI":"10.1007\/5584_2024_846"},{"key":"1783_CR65","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","volume":"4","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62.","journal-title":"Signal Transduct Target Ther"},{"key":"1783_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020332","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Peng H. The role of N(6)-methyladenosine (m(6)A) methylation modifications in hematological malignancies. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14020332.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1783_CR67","first-page":"699","volume":"133","author":"QY Xu","year":"2020","unstructured":"Xu QY, Yu L. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors. Chin Med J (Engl). 2020;133(6):699\u2013715.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"1783_CR68","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1515\/biol-2016-0044","volume":"11","author":"V Borutinskaite","year":"2016","unstructured":"Borutinskaite V, Bauraite-Akatova J, Navakauskiene RJOLS. Anti-leukemic activity of DNA methyltransferase inhibitor procaine targeted on human leukaemia cells. Open Life Sci. 2016;11(1):322\u201330.","journal-title":"Open Life Sci"},{"issue":"1","key":"1783_CR69","first-page":"158","volume":"22","author":"YL Chen","year":"2018","unstructured":"Chen YL, et al. Regulation of DNA methylation and tumor suppression gene expression by miR-29b in leukemia patients and related mechanisms. Eur Rev Med Pharmacol Sci. 2018;22(1):158\u201365.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"1783_CR70","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jha2.663","volume":"4","author":"IM Bouligny","year":"2023","unstructured":"Bouligny IM, et al. Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia. EJHaem. 2023;4(2):381\u201392.","journal-title":"EJHaem"},{"issue":"13","key":"1783_CR71","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1080\/10428194.2023.2252948","volume":"64","author":"L Li","year":"2023","unstructured":"Li L, et al. Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Leuk Lymphoma. 2023;64(13):2113\u201322.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"1783_CR72","first-page":"EVIDoa2200034","volume":"1","author":"K Sasaki","year":"2022","unstructured":"Sasaki K, et al. Low-dose decitabine versus low-dose azacitidine in lower-risk MDS. N Engl J Med Evid. 2022;1(10):EVIDoa2200034.","journal-title":"N Engl J Med Evid"},{"issue":"13","key":"1783_CR73","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","volume":"130","author":"E Jabbour","year":"2017","unstructured":"Jabbour E, et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN. Blood. 2017;130(13):1514\u201322.","journal-title":"Blood"},{"issue":"12","key":"1783_CR74","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/ajh.26667","volume":"97","author":"NJ Short","year":"2022","unstructured":"Short NJ, Kantarjian H. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: past discoveries and future directions. Am J Hematol. 2022;97(12):1616\u201326.","journal-title":"Am J Hematol"},{"key":"1783_CR75","unstructured":"Magalh\u00e3es \u00c2IM. Anti-neoplastic activity of newly synthetized DNMTi in urological tumors. 2017, Universidade do Porto (Portugal)."},{"issue":"6","key":"1783_CR76","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1021\/acschembio.3c00065","volume":"18","author":"CC Cho","year":"2023","unstructured":"Cho CC, et al. Mechanistic insights into harmine-mediated inhibition of human DNA methyltransferases and prostate cancer cell growth. ACS Chem Biol. 2023;18(6):1335\u201350.","journal-title":"ACS Chem Biol"},{"issue":"8","key":"1783_CR77","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/cts.13548","volume":"16","author":"AB Kagan","year":"2023","unstructured":"Kagan AB, et al. DNA methyltransferase inhibitor exposure-response: challenges and opportunities. Clin Transl Sci. 2023;16(8):1309\u201322.","journal-title":"Clin Transl Sci"},{"key":"1783_CR78","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bcmd.2019.03.010","volume":"77","author":"L Ye","year":"2019","unstructured":"Ye L, et al. Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged \u226560 years and has lower toxicities: comparison with low-dose chemotherapy. Blood Cells Mol Dis. 2019;77:88\u201394.","journal-title":"Blood Cells Mol Dis"},{"issue":"10","key":"1783_CR79","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.7150\/jca.56207","volume":"12","author":"L Ye","year":"2021","unstructured":"Ye L, et al. Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study. J Cancer. 2021;12(10):2975\u201381.","journal-title":"J Cancer"},{"issue":"6","key":"1783_CR80","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","volume":"136","author":"G Garcia-Manero","year":"2020","unstructured":"Garcia-Manero G, et al. Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study. Blood. 2020;136(6):674\u201383.","journal-title":"Blood"},{"issue":"1","key":"1783_CR81","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1186\/s12885-022-10073-w","volume":"22","author":"TK Moyo","year":"2022","unstructured":"Moyo TK, et al. The ABNL-MARRO 001 study: a phase 1\u20132 study of randomly allocated active myeloid target compound combinations in MDS\/MPN overlap syndromes. BMC Cancer. 2022;22(1):1013.","journal-title":"BMC Cancer"},{"issue":"10","key":"1783_CR82","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.bbmt.2018.06.016","volume":"24","author":"M de Lima","year":"2018","unstructured":"de Lima M, et al. CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes. Biol Blood Marrow Transpl. 2018;24(10):2017\u201324.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"26","key":"1783_CR83","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383(26):2526\u201337.","journal-title":"N Engl J Med"},{"issue":"2","key":"1783_CR84","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216\u201328.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1783_CR85","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ajh.25198","volume":"93","author":"M Ohanian","year":"2018","unstructured":"Ohanian M, et al. Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia. Am J Hematol. 2018;93(9):1136\u201341.","journal-title":"Am J Hematol"},{"issue":"16","key":"1783_CR86","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386(16):1519\u201331.","journal-title":"N Engl J Med"},{"key":"1783_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010209","author":"D Ruzic","year":"2022","unstructured":"Ruzic D, et al. Targeting histone deacetylases: opportunities for cancer treatment and chemoprevention. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14010209.","journal-title":"Pharmaceutics"},{"issue":"21","key":"1783_CR88","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.34974","volume":"129","author":"R Parveen","year":"2023","unstructured":"Parveen R, Harihar D, Chatterji BP. Recent histone deacetylase inhibitors in cancer therapy. Cancer. 2023;129(21):3372\u201380.","journal-title":"Cancer"},{"key":"1783_CR89","doi-asserted-by":"crossref","first-page":"576946","DOI":"10.3389\/fcell.2020.576946","volume":"8","author":"G Li","year":"2020","unstructured":"Li G, Tian Y, Zhu WG. The roles of histone deacetylases and their inhibitors in cancer therapy. Front Cell Dev Biol. 2020;8:576946.","journal-title":"Front Cell Dev Biol"},{"key":"1783_CR90","doi-asserted-by":"crossref","first-page":"689962","DOI":"10.3389\/fcell.2021.689962","volume":"9","author":"VM Aspri\u0163oiu","year":"2021","unstructured":"Aspri\u0163oiu VM, et al. Epigenetic regulation of angiogenesis in development and tumors progression: potential implications for cancer treatment. Front Cell Dev Biol. 2021;9:689962.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1783_CR91","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s40001-024-02108-8","volume":"29","author":"MS Hosseini","year":"2024","unstructured":"Hosseini MS, et al. Histone deacetylase inhibitors for leukemia treatment: current status and future directions. Eur J Med Res. 2024;29(1):514.","journal-title":"Eur J Med Res"},{"key":"1783_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153862","author":"C Mayr","year":"2021","unstructured":"Mayr C, et al. HDAC screening identifies the HDAC class I inhibitor Romidepsin as a promising epigenetic drug for biliary tract cancer. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13153862.","journal-title":"Cancers (Basel)"},{"issue":"15","key":"1783_CR93","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2174\/0929867325666181016163110","volume":"27","author":"L Cappellacci","year":"2020","unstructured":"Cappellacci L, et al. Recent progress in histone deacetylase inhibitors as anticancer agents. Curr Med Chem. 2020;27(15):2449\u201393.","journal-title":"Curr Med Chem"},{"issue":"7","key":"1783_CR94","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.2174\/0929867327666200203113926","volume":"28","author":"E Pojani","year":"2021","unstructured":"Pojani E, Barlocco D. Romidepsin (FK228), a histone deacetylase inhibitor and its analogues in cancer chemotherapy. Curr Med Chem. 2021;28(7):1290\u2013303.","journal-title":"Curr Med Chem"},{"issue":"1","key":"1783_CR95","first-page":"22","volume":"6","author":"L Barbarotta","year":"2015","unstructured":"Barbarotta L, Hurley K. Romidepsin for the treatment of peripheral T-cell lymphoma. J Adv Pract Oncol. 2015;6(1):22\u201336.","journal-title":"J Adv Pract Oncol"},{"key":"1783_CR96","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12185-017-2286-1","volume":"106","author":"D Maruyama","year":"2017","unstructured":"Maruyama D, et al. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I\/II and pharmacokinetics study. Int J Hematol. 2017;106:655\u201365.","journal-title":"Int J Hematol"},{"issue":"12","key":"1783_CR97","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","volume":"87","author":"AD Bondarev","year":"2021","unstructured":"Bondarev AD, et al. Recent developments of HDAC inhibitors: emerging indications and novel molecules. Br J Clin Pharmacol. 2021;87(12):4577\u201397.","journal-title":"Br J Clin Pharmacol"},{"key":"1783_CR98","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejphar.2017.02.014","volume":"799","author":"G Valiulien\u0117","year":"2017","unstructured":"Valiulien\u0117 G, et al. Anti-leukemic effects of HDACi Belinostat and HMTi 3-deazaneplanocin A on human acute promyelocytic leukemia cells. Eur J Pharmacol. 2017;799:143\u201353.","journal-title":"Eur J Pharmacol"},{"key":"1783_CR99","doi-asserted-by":"crossref","first-page":"115212","DOI":"10.1016\/j.biopha.2023.115212","volume":"165","author":"N El Omari","year":"2023","unstructured":"El Omari N, et al. Anticancer clinical efficiency and stochastic mechanisms of belinostat. Biomed Pharmacother. 2023;165:115212.","journal-title":"Biomed Pharmacother"},{"key":"1783_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184700","author":"A Wawruszak","year":"2021","unstructured":"Wawruszak A, et al. Vorinostat (SAHA) and breast cancer: an overview. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13184700.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1783_CR101","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/10428194.2016.1247956","volume":"58","author":"AJ Moskowitz","year":"2017","unstructured":"Moskowitz AJ, Horwitz SM. Targeting histone deacetylases in T-cell lymphoma. Leuk Lymphoma. 2017;58(6):1306\u201319.","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"1783_CR102","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0959-8049(21)00659-6","volume":"156","author":"E Rem\u00e1k","year":"2021","unstructured":"Rem\u00e1k E, et al. Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and S\u00e9zary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data. Eur J Cancer. 2021;156(Suppl 1):S18.","journal-title":"Eur J Cancer"},{"issue":"13","key":"1783_CR103","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e34033","volume":"10","author":"A Oikonomou","year":"2024","unstructured":"Oikonomou A, et al. Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening. Heliyon. 2024;10(13): e34033.","journal-title":"Heliyon"},{"key":"1783_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111794","author":"E San Jos\u00e9-En\u00e9riz","year":"2019","unstructured":"San Jos\u00e9-En\u00e9riz E, et al. HDAC inhibitors in acute myeloid leukemia. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11111794.","journal-title":"Cancers (Basel)"},{"issue":"1\u20132","key":"1783_CR105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.seminoncol.2023.03.006","volume":"50","author":"D Pan","year":"2023","unstructured":"Pan D, et al. Outcomes with panobinostat in heavily pretreated multiple myeloma patients. Semin Oncol. 2023;50(1\u20132):40\u20138.","journal-title":"Semin Oncol"},{"key":"1783_CR106","doi-asserted-by":"crossref","first-page":"173050","DOI":"10.1016\/j.ejphar.2020.173050","volume":"875","author":"M Mehrpouri","year":"2020","unstructured":"Mehrpouri M, et al. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: shedding light on mitigating effects of NF-\u03baB and autophagy on panobinostat cytotoxicity. Eur J Pharmacol. 2020;875:173050.","journal-title":"Eur J Pharmacol"},{"key":"1783_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094502","author":"MW Lato","year":"2021","unstructured":"Lato MW, et al. The new therapeutic strategies in pediatric T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22094502.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1783_CR108","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/hon.3088","volume":"41","author":"HY Cao","year":"2023","unstructured":"Cao HY, et al. Chidamide: targeting epigenetic regulation in the treatment of hematological malignancy. Hematol Oncol. 2023;41(3):301\u20139.","journal-title":"Hematol Oncol"},{"issue":"13","key":"1783_CR109","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2217\/fon-2016-0526","volume":"13","author":"RM Connolly","year":"2017","unstructured":"Connolly RM, Rudek MA, Piekarz R. Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncol. 2017;13(13):1137\u201348.","journal-title":"Future Oncol"},{"key":"1783_CR110","doi-asserted-by":"crossref","first-page":"116583","DOI":"10.1016\/j.lfs.2019.116583","volume":"232","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, et al. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1\/HO-1 pathway. Life Sci. 2019;232:116583.","journal-title":"Life Sci"},{"issue":"3","key":"1783_CR111","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bjh.13832","volume":"172","author":"T Prebet","year":"2016","unstructured":"Prebet T, et al. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. Br J Haematol. 2016;172(3):384\u201391.","journal-title":"Br J Haematol"},{"key":"1783_CR112","volume":"12","author":"J Fang","year":"2024","unstructured":"Fang J, et al. The epigenetic role of EZH2 in acute myeloid leukemia. PeerJ. 2024;12: e18656.","journal-title":"PeerJ"},{"key":"1783_CR113","doi-asserted-by":"crossref","first-page":"1170394","DOI":"10.3389\/fonc.2023.1170394","volume":"13","author":"A Rivero","year":"2023","unstructured":"Rivero A, et al. Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review. Front Oncol. 2023;13:1170394.","journal-title":"Front Oncol"},{"issue":"1","key":"1783_CR114","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1038\/s41467-024-47701-x","volume":"15","author":"P Romero","year":"2024","unstructured":"Romero P, et al. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition. Nat Commun. 2024;15(1):3452.","journal-title":"Nat Commun"},{"issue":"11","key":"1783_CR115","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433\u201342.","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"1783_CR116","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood-2022-166991","volume":"140","author":"CL Batlevi","year":"2022","unstructured":"Batlevi CL, et al. Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed\/refractory follicular lymphoma: phase 1b results of symphony-1. Blood. 2022;140(Supplement 1):2296\u20138.","journal-title":"Blood"},{"issue":"8","key":"1783_CR117","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41408-021-00539-8","volume":"11","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, et al. Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed\/refractory follicular lymphoma: final analysis of a phase Ib\/II trial. Blood Cancer J. 2021;11(8):147.","journal-title":"Blood Cancer J"},{"issue":"52","key":"1783_CR118","doi-asserted-by":"crossref","first-page":"15988","DOI":"10.1073\/pnas.1521740112","volume":"112","author":"J Yin","year":"2015","unstructured":"Yin J, et al. Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity. Proc Natl Acad Sci U S A. 2015;112(52):15988\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1783_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102699","author":"JC Reneau","year":"2022","unstructured":"Reneau JC, et al. Extranodal natural killer\/T-cell lymphomas: current approaches and future directions. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11102699.","journal-title":"J Clin Med"},{"issue":"2","key":"1783_CR120","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2643-3230.BCD-21-0098","volume":"3","author":"BL Mundy-Bosse","year":"2022","unstructured":"Mundy-Bosse BL, et al. Identification and targeting of the developmental blockade in extranodal natural killer\/T-cell lymphoma. Blood Cancer Discov. 2022;3(2):154\u201369.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"1783_CR121","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1038\/s41598-021-84708-6","volume":"11","author":"JM Kempf","year":"2021","unstructured":"Kempf JM, et al. Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML. Sci Rep. 2021;11(1):5838.","journal-title":"Sci Rep"},{"issue":"1","key":"1783_CR122","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","volume":"13","author":"S Zehtabcheh","year":"2025","unstructured":"Zehtabcheh S, et al. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies. Biomark Res. 2025;13(1):73.","journal-title":"Biomark Res"},{"issue":"4","key":"1783_CR123","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1084\/jem.20181276","volume":"216","author":"F Basheer","year":"2019","unstructured":"Basheer F, et al. Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. J Exp Med. 2019;216(4):966\u201381.","journal-title":"J Exp Med"},{"issue":"6","key":"1783_CR124","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.gendis.2022.03.004","volume":"10","author":"T Ma","year":"2023","unstructured":"Ma T, et al. BET in hematologic tumors: immunity, pathogenesis, clinical trials and drug combinations. Genes Dis. 2023;10(6):2306\u201319.","journal-title":"Genes Dis"},{"key":"1783_CR125","unstructured":"Kubaev A et al. Platelet-derived extracellular vesicles: emerging players in hemostasis and thrombosis. J Liposome Res. vol 25. 2025. 1\u201311."},{"key":"1783_CR126","doi-asserted-by":"crossref","first-page":"23770","DOI":"10.1038\/srep23770","volume":"6","author":"M Huang","year":"2016","unstructured":"Huang M, et al. BET bromodomain suppression inhibits VEGF-induced angiogenesis and vascular permeability by blocking VEGFR2-mediated activation of PAK1 and eNOS. Sci Rep. 2016;6:23770.","journal-title":"Sci Rep"},{"issue":"1","key":"1783_CR127","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/ATVBAHA.123.319909","volume":"44","author":"A Tzani","year":"2024","unstructured":"Tzani A, et al. FAM222A, Part of the BET-regulated basal endothelial transcriptome, is a novel determinant of endothelial biology and angiogenesis-brief report. Arterioscler Thromb Vasc Biol. 2024;44(1):143\u201355.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1783_CR128","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fonc.2019.00016","volume":"9","author":"FV Pericole","year":"2019","unstructured":"Pericole FV, et al. BRD4 inhibition enhances azacitidine efficacy in acute myeloid leukemia and myelodysplastic syndromes. Front Oncol. 2019;9:16.","journal-title":"Front Oncol"},{"issue":"1","key":"1783_CR129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-017-0463-6","volume":"10","author":"C Saygin","year":"2017","unstructured":"Saygin C, Carraway HE. Emerging therapies for acute myeloid leukemia. J Hematol Oncol. 2017;10(1):93.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"1783_CR130","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.2021013156","volume":"139","author":"CP Mill","year":"2022","unstructured":"Mill CP, et al. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022;139(6):907\u201321.","journal-title":"Blood"},{"issue":"8","key":"1783_CR131","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41571-019-0190-8","volume":"16","author":"D Sermer","year":"2019","unstructured":"Sermer D, et al. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol. 2019;16(8):494\u2013507.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1783_CR132","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","volume":"124","author":"GI Shapiro","year":"2021","unstructured":"Shapiro GI, et al. A phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer. 2021;124(4):744\u201353.","journal-title":"Br J Cancer"},{"issue":"11","key":"1783_CR133","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1021\/acs.molpharmaceut.8b00880","volume":"15","author":"J Gu","year":"2018","unstructured":"Gu J, et al. The BET bromodomain inhibitor OTX015 synergizes with targeted agents in multiple myeloma. Mol Pharm. 2018;15(11):5387\u201396.","journal-title":"Mol Pharm"},{"key":"1783_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041877","author":"T Servidei","year":"2021","unstructured":"Servidei T, et al. The BET inhibitor OTX015 exhibits in vitro and in vivo antitumor activity in pediatric ependymoma stem cell models. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22041877.","journal-title":"Int J Mol Sci"},{"key":"1783_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235989","author":"LC Godfrey","year":"2022","unstructured":"Godfrey LC, Rodriguez-Meira A. Viewing AML through a new lens: technological advances in the study of epigenetic regulation. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14235989.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1783_CR136","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood.2020006425","volume":"137","author":"Y Gong","year":"2021","unstructured":"Gong Y, et al. A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the \u03b3-globin gene in \u03b2-thalassemia. Blood. 2021;137(12):1652\u20137.","journal-title":"Blood"},{"issue":"1","key":"1783_CR137","doi-asserted-by":"crossref","first-page":"36","DOI":"10.15283\/ijsc.2016.9.1.36","volume":"9","author":"S Sharma","year":"2016","unstructured":"Sharma S, Gurudutta G. Epigenetic regulation of hematopoietic stem cells. Int J Stem Cells. 2016;9(1):36\u201343.","journal-title":"Int J Stem Cells"},{"key":"1783_CR138","unstructured":"Malcom C. The histone H3, lysine 79 methyltransferase activity of DOT1L is necessary for murine yolk sac erythro-myeloid progenitor self-renewal and erythroblast survival.page 1-102, 2017."},{"key":"1783_CR139","doi-asserted-by":"crossref","first-page":"813503","DOI":"10.3389\/fcell.2021.813503","volume":"9","author":"CA Malcom","year":"2021","unstructured":"Malcom CA, et al. Primitive erythropoiesis in the mouse is independent of DOT1L methyltransferase activity. Front Cell Dev Biol. 2021;9:813503.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1783_CR140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41556-020-00620-7","volume":"23","author":"M Nakamura","year":"2021","unstructured":"Nakamura M, et al. CRISPR technologies for precise epigenome editing. Nat Cell Biol. 2021;23(1):11\u201322.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"1783_CR141","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nbt.3199","volume":"33","author":"IB Hilton","year":"2015","unstructured":"Hilton IB, et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol. 2015;33(5):510\u20137.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"1783_CR142","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cell.2018.03.052","volume":"173","author":"AC Bester","year":"2018","unstructured":"Bester AC, et al. An integrated genome-wide CRISPRa approach to functionalize lncRNAs in drug resistance. Cell. 2018;173(3):649-664.e20.","journal-title":"Cell"},{"key":"1783_CR143","doi-asserted-by":"crossref","first-page":"16026","DOI":"10.1038\/ncomms16026","volume":"8","author":"Y Lei","year":"2017","unstructured":"Lei Y, et al. Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein. Nat Commun. 2017;8:16026.","journal-title":"Nat Commun"},{"issue":"8","key":"1783_CR144","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMra2021838","volume":"384","author":"AT Taher","year":"2021","unstructured":"Taher AT, Musallam KM, Cappellini MD. \u03b2-thalassemias. N Engl J Med. 2021;384(8):727\u201343.","journal-title":"N Engl J Med"},{"key":"1783_CR145","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.freeradbiomed.2021.02.028","volume":"166","author":"A Allen","year":"2021","unstructured":"Allen A, et al. Oxidative status in the \u03b2-thalassemia syndromes in Sri Lanka; a cross-sectional survey. Free Radic Biol Med. 2021;166:337\u201347.","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"1783_CR146","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.3324\/haematol.2016.155655","volume":"102","author":"S Mettananda","year":"2017","unstructured":"Mettananda S, et al. Selective silencing of \u03b1-globin by the histone demethylase inhibitor IOX1: a potentially new pathway for treatment of \u03b2-thalassemia. Haematologica. 2017;102(3):e80\u20134.","journal-title":"Haematologica"},{"issue":"1","key":"1783_CR147","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1038\/s41598-019-48204-2","volume":"9","author":"S Mettananda","year":"2019","unstructured":"Mettananda S, et al. Synergistic silencing of \u03b1-globin and induction of \u03b3-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for \u03b2-thalassaemia. Sci Rep. 2019;9(1):11649.","journal-title":"Sci Rep"},{"issue":"3","key":"1783_CR148","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, et al. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2021;384(3):252\u201360.","journal-title":"N Engl J Med"},{"issue":"5","key":"1783_CR149","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/bloodadvances.2020001996","volume":"5","author":"G Pavani","year":"2021","unstructured":"Pavani G, et al. Correction of \u03b2-thalassemia by CRISPR\/Cas9 editing of the \u03b1-globin locus in human hematopoietic stem cells. Blood Adv. 2021;5(5):1137\u201353.","journal-title":"Blood Adv"},{"issue":"3","key":"1783_CR150","first-page":"28","volume":"11","author":"A Noroozi Aghide","year":"2016","unstructured":"Noroozi Aghide A, Soleimani Samarkhazan H, Ahmadnezhad M. Effect of harmine alkaloid on the expression of P16 and DAPK in HL60 leukemia cell line. Paramed Sci Military Health. 2016;11(3):28\u201333.","journal-title":"Paramed Sci Military Health"},{"issue":"1","key":"1783_CR151","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00204-021-03174-1","volume":"96","author":"V Wachholz","year":"2022","unstructured":"Wachholz V, et al. Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch Toxicol. 2022;96(1):177\u201393.","journal-title":"Arch Toxicol"},{"issue":"2","key":"1783_CR152","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/hematolrep15020035","volume":"15","author":"S Takahashi","year":"2023","unstructured":"Takahashi S. Combination therapies with kinase inhibitors for acute myeloid leukemia treatment. Hematol Rep. 2023;15(2):331\u201346.","journal-title":"Hematol Rep"},{"issue":"1","key":"1783_CR153","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, et al. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1783_CR154","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-020-01540-1","volume":"9","author":"S Majothi","year":"2020","unstructured":"Majothi S, et al. FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research-a systematic review and meta-analysis. Syst Rev. 2020;9(1): 285.","journal-title":"Syst Rev"},{"key":"1783_CR155","volume":"52","author":"JC Zhao","year":"2022","unstructured":"Zhao JC, et al. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2022;52: 100905.","journal-title":"Blood Rev"},{"key":"1783_CR156","doi-asserted-by":"crossref","first-page":"578011","DOI":"10.3389\/fgene.2020.578011","volume":"11","author":"L Hontecillas-Prieto","year":"2020","unstructured":"Hontecillas-Prieto L, et al. Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials. Front Genet. 2020;11:578011.","journal-title":"Front Genet"},{"key":"1783_CR157","volume":"226","author":"M Zhou","year":"2021","unstructured":"Zhou M, et al. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. Eur J Med Chem. 2021;226: 113825.","journal-title":"Eur J Med Chem"},{"key":"1783_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/nu10060731","author":"AK Singh","year":"2018","unstructured":"Singh AK, Bishayee A, Pandey AK. Targeting histone deacetylases with natural and synthetic agents: an emerging anticancer strategy. Nutrients. 2018. https:\/\/doi.org\/10.3390\/nu10060731.","journal-title":"Nutrients"},{"issue":"1","key":"1783_CR159","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s11033-024-10084-9","volume":"51","author":"H Hu","year":"2024","unstructured":"Hu H, et al. Effects of a novel HDAC6-selective inhibitor\u2019s radiosensitization on cancer cells. Mol Biol Rep. 2024;51(1):1151.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"1783_CR160","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/CMR.0000000000000818","volume":"32","author":"JS Weber","year":"2022","unstructured":"Weber JS, et al. Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III\/IV melanoma. Melanoma Res. 2022;32(5):324\u201333.","journal-title":"Melanoma Res"},{"issue":"5","key":"1783_CR161","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.apsb.2019.09.006","volume":"10","author":"X Chen","year":"2020","unstructured":"Chen X, et al. Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm Sin B. 2020;10(5):723\u201333.","journal-title":"Acta Pharm Sin B"},{"key":"1783_CR162","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4018\/979-8-3693-3976-3.ch005","volume-title":"Critical developments in cancer immunotherapy","author":"M-S Hosseini","year":"2024","unstructured":"Hosseini M-S, Akbarzadeh MA, Jadidi-Niaragh F. Myeloid-derived suppressor cells and macrophage polarization in cancer immunotherapy. In: Sheykhhasan M, Yang P, Poondla N, editors. Critical developments in cancer immunotherapy. Hershey, PA, USA: IGI Global; 2024. p. 157\u2013204."},{"issue":"1","key":"1783_CR163","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10238-025-01588-0","volume":"25","author":"A Raoufi","year":"2025","unstructured":"Raoufi A, et al. Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets. Clin Exp Med. 2025;25(1):73.","journal-title":"Clin Exp Med"},{"issue":"11","key":"1783_CR164","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1158\/0008-5472.CAN-15-2249","volume":"76","author":"R Pathania","year":"2016","unstructured":"Pathania R, et al. Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth. Cancer Res. 2016;76(11):3224\u201335.","journal-title":"Cancer Res"},{"key":"1783_CR165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/bs.acr.2023.01.001","volume":"158","author":"A Kumar","year":"2023","unstructured":"Kumar A, et al. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors. Adv Cancer Res. 2023;158:73\u2013161.","journal-title":"Adv Cancer Res"},{"issue":"1","key":"1783_CR166","volume":"10","author":"W Huang","year":"2024","unstructured":"Huang W, et al. Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer. Cell Death Discov. 2024;10(1): 143.","journal-title":"Cell Death Discov"},{"issue":"17","key":"1783_CR167","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","volume":"140","author":"ES Wang","year":"2022","unstructured":"Wang ES, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845\u201357.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1783_CR168","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/blood-2024-203569","volume":"144","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, et al. Results from a phase 1 open-label dose escalation and expansion trial of oral azacitidine + cedazuridine (ASTX030) in patients with myelodysplastic syndromes (MDS) and MDS\/myeloproliferative neoplasms (MPN). Blood. 2024;144(Supplement 1):662\u2013662.","journal-title":"Blood"},{"issue":"18","key":"1783_CR169","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","volume":"390","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, et al. Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia. N Engl J Med. 2024;390(18):1663\u201376.","journal-title":"N Engl J Med"},{"issue":"3","key":"1783_CR170","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/cas.14822","volume":"112","author":"W Munakata","year":"2021","unstructured":"Munakata W, et al. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma. Cancer Sci. 2021;112(3):1123\u201331.","journal-title":"Cancer Sci"},{"issue":"9","key":"1783_CR171","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1111\/cas.15040","volume":"112","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, et al. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. Cancer Sci. 2021;112(9):3627\u201335.","journal-title":"Cancer Sci"},{"issue":"4","key":"1783_CR172","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","volume":"3","author":"C Berthon","year":"2016","unstructured":"Berthon C, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 2016;3(4):e186\u201395.","journal-title":"Lancet Haematol"},{"issue":"13","key":"1783_CR173","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.20.02619","volume":"39","author":"G Garcia-Manero","year":"2021","unstructured":"Garcia-Manero G, et al. Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2021;39(13):1426\u201336.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1783_CR174","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2024-203459","volume":"144","author":"IM Bouligny","year":"2024","unstructured":"Bouligny IM, et al. A phase II trial of venetoclax in combination with cladribine, idarubicin, and cytarabine in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2024;144(Supplement 1):734\u2013734.","journal-title":"Blood"},{"issue":"7","key":"1783_CR175","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1158\/1078-0432.CCR-23-2234","volume":"30","author":"A Woods","year":"2024","unstructured":"Woods A, et al. FDA approval summary: Ivosidenib in combination with azacitidine for treatment of patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. Clin Cancer Res. 2024;30(7):1226\u201331.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"1783_CR176","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.2023020301","volume":"142","author":"S Loo","year":"2023","unstructured":"Loo S, et al. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG. Blood. 2023;142(23):1960\u201371.","journal-title":"Blood"},{"issue":"22","key":"1783_CR177","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz RL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827\u201334.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1783_CR178","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1182\/blood-2022-157201","volume":"140","author":"SK Barta","year":"2022","unstructured":"Barta SK, et al. A phase I trial assessing the feasibility of Romidepsin combined with Brentuximab Vedotin for patients requiring systemic therapy for cutaneous T-cell lymphoma. Blood. 2022;140(Supplement 1):6543\u20134.","journal-title":"Blood"},{"issue":"5","key":"1783_CR179","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2174\/1871520620666200918113625","volume":"21","author":"H Mirzaei","year":"2021","unstructured":"Mirzaei H, et al. Anti-cancer activity of curcumin on multiple myeloma. Anticancer Agents Med Chem. 2021;21(5):575\u201386.","journal-title":"Anticancer Agents Med Chem"},{"issue":"1","key":"1783_CR180","volume":"10","author":"BH Lee","year":"2020","unstructured":"Lee BH, et al. Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study. Sci Rep. 2020;10(1): 39.","journal-title":"Sci Rep"},{"issue":"5","key":"1783_CR181","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.leukres.2015.03.006","volume":"39","author":"M Cabrero","year":"2015","unstructured":"Cabrero M, et al. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leuk Res. 2015;39(5):520\u20134.","journal-title":"Leuk Res"},{"issue":"6","key":"1783_CR182","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","volume":"13","author":"T Liang","year":"2023","unstructured":"Liang T, et al. Targeting histone deacetylases for cancer therapy: trends and challenges. Acta Pharm Sin B. 2023;13(6):2425\u201363.","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"1783_CR183","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2016.154377","volume":"102","author":"V Ribrag","year":"2017","unstructured":"Ribrag V, et al. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica. 2017;102(5):903\u20139.","journal-title":"Haematologica"},{"key":"1783_CR184","doi-asserted-by":"crossref","first-page":"752278","DOI":"10.3389\/fgeed.2021.752278","volume":"3","author":"S Mettananda","year":"2021","unstructured":"Mettananda S. Genetic and epigenetic therapies for \u03b2-thalassaemia by altering the expression of \u03b1-globin gene. Front Genome Ed. 2021;3:752278.","journal-title":"Front Genome Ed"},{"issue":"5","key":"1783_CR185","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-15-0905","volume":"22","author":"AB Patel","year":"2016","unstructured":"Patel AB, Vellore NA, Deininger MW. New strategies in myeloproliferative neoplasms: the evolving genetic and therapeutic landscape. Clin Cancer Res. 2016;22(5):1037\u201347.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1783_CR186","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13046-023-02841-8","volume":"42","author":"E Peroni","year":"2023","unstructured":"Peroni E, et al. Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. Dissect cancer heterogeneity and tailor the treatment. J Exp Clin Cancer Res. 2023;42(1):259.","journal-title":"J Exp Clin Cancer Res"},{"key":"1783_CR187","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.exphem.2020.06.003","volume":"87","author":"B Yan","year":"2020","unstructured":"Yan B, et al. AML chemoresistance: the role of mutant TP53 subclonal expansion and therapy strategy. Exp Hematol. 2020;87:13\u20139.","journal-title":"Exp Hematol"},{"issue":"9","key":"1783_CR188","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.3390\/ijms26094005","volume":"26","author":"S Cao","year":"2025","unstructured":"Cao S, Wang Q, Zhu GJIJoMS. From chemotherapy to targeted therapy: unraveling resistance in acute myeloid leukemia through genetic and non-genetic insights. Int J Mol Sci. 2025;26(9):4005.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1783_CR189","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1101\/gr.232272.117","volume":"28","author":"M Pellegrino","year":"2018","unstructured":"Pellegrino M, et al. High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics. Genome Res. 2018;28(9):1345\u201352.","journal-title":"Genome Res"},{"issue":"1","key":"1783_CR190","volume":"11","author":"K Morita","year":"2020","unstructured":"Morita K, et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020;11(1): 5327.","journal-title":"Nat Commun"},{"issue":"1","key":"1783_CR191","first-page":"1","volume":"3","author":"M Farrokhi","year":"2023","unstructured":"Farrokhi M, et al. Role of precision medicine and personalized medicine in the treatment of diseases. Kindle. 2023;3(1):1\u2013164.","journal-title":"Kindle"},{"issue":"4","key":"1783_CR192","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/joim.13697","volume":"294","author":"R Rosenquist","year":"2023","unstructured":"Rosenquist R, et al. Novel precision medicine approaches and treatment strategies in hematological malignancies. J Intern Med. 2023;294(4):413\u201336.","journal-title":"J Intern Med"},{"key":"1783_CR193","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194820","author":"R Alves","year":"2021","unstructured":"Alves R, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13194820.","journal-title":"Cancers (Basel)"},{"key":"1783_CR194","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0674","author":"M Zhang","year":"2025","unstructured":"Zhang M, et al. Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial. JAMA Oncol. 2025. https:\/\/doi.org\/10.1001\/jamaoncol.2025.0674.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1783_CR195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","volume":"44","author":"A Suraweera","year":"2025","unstructured":"Suraweera A, O\u2019Byrne KJ, Richard DJ. Epigenetic drugs in cancer therapy. Cancer Metastasis Rev. 2025;44(1):37.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"1783_CR196","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10238-025-01686-z","volume":"25","author":"AK Bishoyi","year":"2025","unstructured":"Bishoyi AK, et al. Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. Clin Exp Med. 2025;25(1):166.","journal-title":"Clin Exp Med"},{"key":"1783_CR197","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.2147\/IJN.S147659","volume":"12","author":"T Briot","year":"2017","unstructured":"Briot T, et al. Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia. Int J Nanomedicine. 2017;12:8427\u201342.","journal-title":"Int J Nanomedicine"},{"key":"1783_CR198","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.2147\/CMAR.S491805","volume":"16","author":"M Duran","year":"2024","unstructured":"Duran M, Kaga E. Evaluation of drug effectiveness and controlled release profiles of clay minerals loaded with anti-carcinogenic agent as a drug delivery system on leukemia. Cancer Manag Res. 2024;16:1775\u201392.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"1783_CR199","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s10238-025-01724-w","volume":"25","author":"A Bayani","year":"2025","unstructured":"Bayani A, et al. Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy. Clin Exp Med. 2025;25(1):186.","journal-title":"Clin Exp Med"},{"issue":"1","key":"1783_CR200","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/s41598-025-85658-z","volume":"15","author":"Q Chen","year":"2025","unstructured":"Chen Q, et al. Exploring liraglutide\u2019s mechanism in reducing renal fibrosis: the Fsp1-CoQ10-NAD(P)H pathway. Sci Rep. 2025;15(1):1754.","journal-title":"Sci Rep"},{"issue":"4","key":"1783_CR201","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1042\/BST20230017","volume":"51","author":"E Gruber","year":"2023","unstructured":"Gruber E, Kats LM. The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches. Biochem Soc Trans. 2023;51(4):1675\u201386.","journal-title":"Biochem Soc Trans"},{"key":"1783_CR202","doi-asserted-by":"crossref","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, et al. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13:927153.","journal-title":"Front Immunol"},{"key":"1783_CR203","doi-asserted-by":"crossref","first-page":"580328","DOI":"10.3389\/fimmu.2020.580328","volume":"11","author":"L Driouk","year":"2020","unstructured":"Driouk L, et al. Chimeric antigen receptor T cells targeting NKG2D-ligands show robust efficacy against acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Front Immunol. 2020;11:580328.","journal-title":"Front Immunol"},{"issue":"4","key":"1783_CR204","first-page":"1022","volume":"106","author":"L Lee","year":"2021","unstructured":"Lee L, et al. A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia. Haematologica. 2021;106(4):1022\u201333.","journal-title":"Haematologica"},{"key":"1783_CR205","unstructured":"Benkirane H. Deep learning methods for the integration of multi-omics and histopathology data for precision medicine in oncology. 2024, Universit\u00e9 Paris-Saclay."},{"key":"1783_CR206","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.108735","volume":"178","author":"\u0391 Kosvyra","year":"2024","unstructured":"Kosvyra \u0391, et al. Machine learning and integrative multi-omics network analysis for survival prediction in acute myeloid leukemia. Comput Biol Med. 2024;178: 108735.","journal-title":"Comput Biol Med"},{"issue":"1","key":"1783_CR207","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11033-025-10527-x","volume":"52","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. C-type lectin-like molecule-1 as a diagnostic, prognostic, and therapeutic marker in leukemia. Mol Biol Rep. 2025;52(1):464.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"1783_CR208","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/leu.2012.342","volume":"27","author":"A Mims","year":"2013","unstructured":"Mims A, et al. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia. 2013;27(4):871\u20138.","journal-title":"Leukemia"},{"key":"1783_CR209","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123657","author":"S Kumar","year":"2020","unstructured":"Kumar S, et al. Non-coding RNAs as mediators of epigenetic changes in malignancies. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12123657.","journal-title":"Cancers (Basel)"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01783-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01783-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01783-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:50:59Z","timestamp":1764917459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01783-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":209,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1783"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01783-z","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}